Table 1.
Patient characteristics
| n | Mean | SD | Min - Max | |
|---|---|---|---|---|
| Examined | 76 | |||
| Enrolled (F:M) | 74 (2.4:1) | |||
| Age (SD) yrs | 11.9 | 3.8 | ||
| Age at onset (SD) yrs | 7.5 | 3.9 | ||
| Disease duration (SD) yrs | 4.5 | 3.4 | ||
| JIA diagnosis: | ||||
| Oligo ANA pos | 17/23% | |||
| Oligo ANA neg | 15/20.3% | |||
| Oligo extended | 6 /8.1% | |||
| Poly RF pos | 16/21.6% | |||
| Poly RF neg | 8/10.8% | |||
| Systemic JIA | 8 (10.8)% | |||
| ERA HLA B27 pos | 3/4% | |||
| Psoriatic Arthritis | 1/1.4% | |||
| Medication: | ||||
| NSAID | 36/48.6% | |||
| Systemic steroids | 4/5.4% | |||
| DMARDS | 41/55.4% | |||
| Biologics | 22/29.7% | |||
| Orthodontic tx | 7/9.5% | |||
| JADAS-27 | 74 | 3.6 | 5.8 | 0 – 37.5 |
| MMO | 74 | 45.3 | 7.7 | 25 – 60 |
| MMO age ≤ 10 | 27 | 43.6 | 5.4 | 25 – 52 |
| MMO age > 10 | 47 | 46.3 | 8.7 | 25 – 60 |
| MMO ≤ 40 | 21 | 35.9 | 4.2 | 25 – 40 |
| MMO ≤ 35 | 8 | 32.1 | 4.5 | 25 – 35 |
| MMO ≤ 30 | 2 | - | - | 25 – 27 |
Number of patients referred to as n / % (unless indicated otherwise), and MMO as mm
Pt: patients; F: female; M: male; yrs: years, SD = standard deviation, n = number of patients. ANA: anti-nuclear antibodies; oligo: oligoarticular; poly: polyarticular; ERA: enthesitis-related arthritis; PsoA: psoriatic arthritis; NSAIDs: non-steroidal anti-inflammatory drugs; DMARDs: disease modifying anti-rheumatic drugs. Orthodontic tx: coincidental orthodontic treatment (patients being in treatment and wearing appliances not for JIA related TMJ issues). MMO: maximum mouth opening; JADAS-27: Juvenile Arthritis Disease Activity Score.